Search details
1.
Magnetic targeting of oncolytic VSV-based therapies improves infection of tumor cells in the presence of virus-specific neutralizing antibodies in vitro.
Biochem Biophys Res Commun
; 526(3): 641-646, 2020 06 04.
Article
in English
| MEDLINE | ID: mdl-32248971
2.
MARCH1 E3 Ubiquitin Ligase Dampens the Innate Inflammatory Response by Modulating Monocyte Functions in Mice.
J Immunol
; 198(2): 852-861, 2017 01 15.
Article
in English
| MEDLINE | ID: mdl-27940660
3.
Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment.
Breast Cancer Res
; 18(1): 83, 2016 08 08.
Article
in English
| MEDLINE | ID: mdl-27503504
4.
Identification of a novel motif that affects the conformation and activity of the MARCH1 E3 ubiquitin ligase.
J Cell Sci
; 126(Pt 4): 989-98, 2013 Feb 15.
Article
in English
| MEDLINE | ID: mdl-23264739
5.
Major histocompatibility complex class-II molecules promote targeting of human immunodeficiency virus type 1 virions in late endosomes by enhancing internalization of nascent particles from the plasma membrane.
Cell Microbiol
; 15(5): 809-22, 2013 May.
Article
in English
| MEDLINE | ID: mdl-23170932
6.
Autoregulation of MARCH1 expression by dimerization and autoubiquitination.
J Immunol
; 188(10): 4959-70, 2012 May 15.
Article
in English
| MEDLINE | ID: mdl-22508929
7.
Cutting edge: HLA-DO impairs the incorporation of HLA-DM into exosomes.
J Immunol
; 187(4): 1547-51, 2011 Aug 15.
Article
in English
| MEDLINE | ID: mdl-21768396
8.
Increased expression of the immunoproteasome subunits PSMB8 and PSMB9 by cancer cells correlate with better outcomes for triple-negative breast cancers.
Sci Rep
; 13(1): 2129, 2023 02 06.
Article
in English
| MEDLINE | ID: mdl-36746983
9.
High Levels of MFG-E8 Confer a Good Prognosis in Prostate and Renal Cancer Patients.
Cancers (Basel)
; 14(11)2022 Jun 04.
Article
in English
| MEDLINE | ID: mdl-35681775
10.
Sorting of MHC class II molecules into exosomes through a ubiquitin-independent pathway.
Traffic
; 10(10): 1518-27, 2009 Oct.
Article
in English
| MEDLINE | ID: mdl-19566897
11.
In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity.
J Immunother Cancer
; 9(2)2021 02.
Article
in English
| MEDLINE | ID: mdl-33608375
12.
The pros and cons of interferons for oncolytic virotherapy.
Cytokine Growth Factor Rev
; 56: 49-58, 2020 12.
Article
in English
| MEDLINE | ID: mdl-32694051
13.
Methionine Metabolism Shapes T Helper Cell Responses through Regulation of Epigenetic Reprogramming.
Cell Metab
; 31(2): 250-266.e9, 2020 02 04.
Article
in English
| MEDLINE | ID: mdl-32023446
14.
Pre-surgical oncolytic virotherapy improves breast cancer outcomes.
Oncoimmunology
; 8(11): e1655363, 2019.
Article
in English
| MEDLINE | ID: mdl-31646102
15.
Pre-surgical neoadjuvant oncolytic virotherapy confers protection against rechallenge in a murine model of breast cancer.
Sci Rep
; 9(1): 1865, 2019 02 12.
Article
in English
| MEDLINE | ID: mdl-30755678
16.
Brief Communication; A Heterologous Oncolytic Bacteria-Virus Prime-Boost Approach for Anticancer Vaccination in Mice.
J Immunother
; 41(3): 125-129, 2018 Apr.
Article
in English
| MEDLINE | ID: mdl-29293165
17.
Enhanced susceptibility of cancer cells to oncolytic rhabdo-virotherapy by expression of Nodamura virus protein B2 as a suppressor of RNA interference.
J Immunother Cancer
; 6(1): 62, 2018 06 19.
Article
in English
| MEDLINE | ID: mdl-29921327
18.
Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade.
J Clin Invest
; 128(10): 4654-4668, 2018 10 01.
Article
in English
| MEDLINE | ID: mdl-30198904
19.
Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy.
Sci Transl Med
; 10(422)2018 01 03.
Article
in English
| MEDLINE | ID: mdl-29298865
20.
Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms.
Cancer Res
; 78(4): 922-937, 2018 02 15.
Article
in English
| MEDLINE | ID: mdl-29259007